Xenazine
XENAZINE: 25 mg, scored tablets
(INN: tetrabenazine)
Xenazine is indicated for the treatment of movement disorders associated with Huntington's chorea and hemiballismus.
Xenazine was developed by Cambridge Laboratories (UK). EUSA holds an exclusive agreement for the distribution of Xenazine in France where it obtained a marketing authorization in France in July 2005.
| Product | Availability | Description |
Xenazine®: |
France |
Xenazine was developed by Cambridge Laboratories (UK) and is indicated for the treatment of movement disorders associated with Huntington's chorea and Hemiballismus. |
For information on our full range of products, where they are available and prescribing information, please see the Summary table.
| Back to home page | Legal | Privacy Policy |
